Curcumin for Joint Pain in Breast Cancer Survivors

Recruiting in Palo Alto (17 mi)

+3 other locations

Overseen by Lisa D Yee, MD

Age: Any Age

Sex: Female

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: City of Hope Medical Center

Approved in 4 Jurisdictions

Trial Summary

What is the purpose of this trial?

This trial studies whether a special form of curcumin can reduce joint pain in breast cancer survivors who have pain from their cancer treatment. Curcumin, found in turmeric, is known for its anti-inflammatory effects. The trial aims to see if this natural substance can help these patients feel better. Curcumin, derived from turmeric, has been used in traditional medicine for centuries and has shown potential anticancer and anti-inflammatory properties in various studies.

Eligibility Criteria

This trial is for postmenopausal breast cancer survivors with joint pain due to aromatase inhibitors. Participants must have had surgery for estrogen/progesterone-positive breast cancer and been on FDA-approved aromatase inhibitors for at least 90 days, planning to continue them. They should have a history of joint pain starting or worsening with the therapy.

Inclusion Criteria

I have been on an FDA-approved aromatase inhibitor for at least 90 days and plan to continue.

I have completed surgery for breast cancer, either mastectomy or lumpectomy.

I am postmenopausal or on treatment to suppress my ovaries for taking AIs.

Exclusion Criteria

I have not used strong painkillers, except for NSAIDs or acetaminophen, in the last 14 days and won't during the study.

I haven't had cancer in the last 5 years, except for certain skin cancers, cervical cancer in situ, or early-stage cancers I've recovered from.

I have not started any new treatment for joint pain or stiffness in the last 30 days.

Participant Groups

The study tests if curcumin can reduce joint pain in these individuals compared to a placebo. Curcumin is derived from turmeric and may help arthritis-related discomfort. The trial includes taking curcumin or placebo, quality-of-life assessments, and questionnaires about the effect on joint pain.

Group I: Arm I (nanoemulsion curcumin) Experimental Treatment 4 Interventions

Patients receives nanoemulsion curcumin orally (PO) twice daily (BID) for up to 3 months in the absence of disease progression or unacceptable toxicity.

Group II: Arm II (placebo) Placebo Group 1 Intervention

Patients receive placebo PO BID for up to 3 months in the absence of disease progression or unacceptable toxicity.

Curcumin is already approved in United States, European Union, India, China for the following indications:

🇺🇸 Approved in United States as Curcumin for:

• Dietary Supplement

🇪🇺 Approved in European Union as Curcuma for:

• Herbal Medicinal Product

🇮🇳 Approved in India as Haldi for:

• Traditional Medicine

🇨🇳 Approved in China as Jiang Huang for:

• Traditional Chinese Medicine

Find a Clinic Near You

Research Locations Nearby Select from list below to view details:

City of Hope South Pasadena South Pasadena, CA

Ohio State University Comprehensive Cancer Center Columbus, OH

City of Hope Rancho Cucamonga Rancho Cucamonga, CA

City of Hope Medical Center Duarte, CA

Who Is Running the Clinical Trial?

City of Hope Medical Center Lead Sponsor

National Cancer Institute (NCI) Collaborator

References